Introduction
Angiotensin II (AII) exerts many biological effects such as cell contraction, proliferation, and migration of vascular kinase pathway (4) . AT1R antagonists have been widely used in the treatment of cardiovascular disease (5) .
Insulin-sensitizing thiazolidinediones, including troglitazone and 15-deoxy-∆ 12, 14 -prostaglandin J2 (PGJ2), are known to activate nuclear peroxisome proliferator-activated receptor (PPAR)-γ as its ligands (6, 7) . Although the function of PPAR-γ and its ligands has thus far been studied mainly in adipocytes (8) , the anti-atherosclerotic effects of PPAR-γ and its ligands have recently been focused in the vasculature (9, 10) . We recently observed that PPAR-γ ligands, including troglitazone and PGJ2, suppressed AT1R gene expression both at the mRNA and protein levels in VSMCs (11, 12) . We also demonstrated that this suppression was mediated by ligand-activated PPAR-γ at the transcription level through the 58/ 34 GC-box related element in the AT1R gene promoter region by the inhibition of Sp1 binding to DNA via a protein-protein interaction (12) .
In addition to its ligands, the function of PPAR-γ itself is reported to be modulated by several factors, including the mitogen-activated protein (MAP) kinase pathway (13) and co-activators such as CREB-binding protein (CBP) and its homolog p300 (14) . The MAP kinase pathway inhibits PPAR-γ activity through its phosphorylation (13) . CBP/p300 interacts with PPAR-γ through its LXXLL motif, and modulates PPAR-γ function (14) . Interestingly, activation of the MAP kinase pathway and CBP/p300 has recently been reported to be atherogenic (15, 16) . We therefore examined the effects of the MAP kinase pathway and CBP on the suppression of PPAR-γ-mediated AT1R gene transcription.
Methods

Plasmids
The following, previously described reporter plasmids containing rat AT1R gene promoter fragments and luciferase cDNA (12) were used for transient transfection studies:
1969/ 104-luc (1969-base pairs (bp) 5 -FL and 104-bp 5 -untranslated region (UTR) of rat AT1R gene); 58/ 1-luc (58-bp 5 -FL); and mutated 58/ 1-luc whose GC-box related sequence within the 58/ 34 region was disrupted (changed from TGCAGAGCAGCGACGCCCCCTAGGC to TGCAGAGCAGCGACGTTTTTTAGGC; mutated sites are underlined). CBP expression plasmid in pCDNA3 (17) was provided by Dr. A. Fukamizu (Tsukuba University, Tsukuba, Japan). β-Galactosidase control plasmid in pCMV was purchased from Clontech (Palo Alto, USA).
Transient Transfection Study/Luciferase Assay
When cultured rat VSMCs reached 70% confluence, the media were changed to stripped media (18) and the cells were incubated for 5-6 h. Then the cells were transfected using lipofectin according to the manufacturer's instructions (Gibco BRL, Gaithersburg, USA). Briefly, 1.2 µg reporter plasmid and 0.8 µg β-galactosidase control plasmid were mixed with 6 µl lipofectin per 3.5 cm plate. In some experiments, several concentrations of CBP expression plasmid were also co-transfected. Twelve h after transfection, the media were replaced with stripped media and the cells were incubated for an additional 12 h. The cells were then incubated either with or without 50 µmol/l troglitazone (provided by Sankyo Co., Ltd., Tokyo, Japan) or 2.5 µmol/l PGJ2 (Cayman Chemical, Ann Arbor, USA) for 12 h, and their luciferase activities were measured. In one experiment, the cells were incubated with 30 µmol/l PD98059 (Calbiochem, La Jolla, USA), a highly specific inhibitor of MAP kinase kinase (19) , or 10 µmol/l SB203580 (Calbiochem), a highly specific inhibitor of p38 kinase (20) , for 12 h with 2.5 µmol/l PGJ2 (the inhibitors were added to the media 30 min before adding PGJ2). After harvesting, the cell extracts were analyzed for both luciferase and β-galactosidase activities (18) to determine the expression of both genes. The transfection efficiency was normalized by the β-galactosidase expression.
RNA Preparation/Semi-Quantitative Reverse Transcription (RT)-Polymelase Chain Reaction (PCR)
When rat VSMCs became 70% confluent, media were changed to stripped media (18) and incubated for 5-6 h. The cells then were incubated either with or without 2.5 µmol/l PGJ2 (Cayman Chemical) for 12 h. In one experiment, 30 µmol/l PD98059 (Calbiochem) (19) was also used (PD-98059 was added to the media 30 min before adding PGJ2). Their total RNAs were then extracted using an RNeasy mini kit (Qiagen, Hilden, Germany), and were subsequently treated with RNase-free DNase (Takara Shuzo, Kyoto, Japan). The extracted RNAs (1 µg) were subjected to RT-PCR using specific primers either for rat AT1R (forward primer: 5 -TGAGACCAACTCAACCCAGA-3 ; reverse primer 5 -GCATTACATTGCCAGTGTG-3 ) (21) and glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) (forward primer: 5 -TCCCTCAAGATTGTCAGCAA-3 ; reverse primer 5 -AGA TCCACAACGGATACATT-3 ) (22) . RT-PCR of AT1R and GAPDH mRNAs was performed simultaneously as follows: 30 min at 50°C and 2 min at 94°C for RT, followed by 30 cycles of 45 s at 94°C, 45 s at 53°C, and 1 min 30 s at 72°C. A linear correlation between PCR cycles and densitometry intensity of PCR products was confirmed (data not shown). The intensity of PCR products was calculated using a Luminous Imager (AI-C, Japan).
Generation of Anti-PPAR-Antibodies/Western Immunoblot Analysis
Anti-PPAR-γ antibody recognizing both PPAR-γ1 and PPAR-γ 2 was raised against synthetic peptides containing mouse PPAR-γ1 (60-79) (23) , and anti-PPAR-γ 2 antibody recognizing PPAR-γ 2 alone was raised against synthetic peptides containing mouse PPAR-γ 2 (14-30) (23) as previ-ously described (24) (Sato et al., unpublished data). The specificity of each antibody was confirmed by Western immunoblot analyses using in vitro translated PPAR-γ1 and -γ 2 proteins (Sato et al., unpublished data). Western immunoblot analyses with these antibodies were performed as previously described (12, 24) using 20 µg of nuclear extracts prepared from VSMCs cultured either in regular media (with 10% fetal bovine serum), regular media plus 30 µmol/l PD-98059 (Calbiochem) (19) , or serum-free media (with 0% fetal bovine serum) for 24 h. Western immunoblot analyses of whole cell extracts of VSMCs using anti-CBP antibody (Santa Cruz Biotechnology, Santa Cruz, USA) were also performed.
Statistical Analyses
Statistical analyses of the transient transfection studies were performed by one-factor analysis of variance (ANOVA) using StatView 4.0 software (ABACUS Concepts, Berkeley, USA).
Results
Effects of MAP Kinase Inhibitors on AT1R Gene Transcription Suppression
Since the MAP kinase pathway is known to inhibit PPAR-γ activity through its phosphorylation (13), we first examined the effects of the MAP kinase inhibitors on PPAR-γ-mediated AT1R gene transcription suppression. We treated 1969/ 104-luc transfected rat VSMCs with 30 µmol/l PD98059, a specific inhibitor of MAP kinase kinase (19) , and 2.5 µmol/l PGJ2 for 12 h. Interestingly, the effect of PGJ2 on the suppression of 1969/ 104-luc transcription was augmented by PD98059 treatment (Fig. 1, lines 2 and 4) . In [2] [3] [4] . The cells were co-incubated either with 10 µmol/l SB203580, a highly specific inhibitor of p38 kinase (20) contrast, treatment with 10 µmol/l SB203580, a highly specific inhibitor of p38 kinase (20) , showed no effects (Fig. 1,  lines 2 and 3 ). PD98059 treatment alone did not affect 1969/ 104-luc activity (Fig. 1, line 5 ). Next, we examined the effects of PD98059 on AT1R mRNA expression. As shown in Fig. 2 , further decrease of AT1R mRNA expression by PD98059 treatment in addition to PGJ2 (line 3) comparing with PGJ2 alone (line 2) was confirmed by semi-quantitative RT-PCR. In order to examine the basal phosphorylation state of PPAR-γ in VSMCs, Western immunoblot analyses using anti-PPAR-γ and anti-PPAR-γ 2 antibodies were performed. As shown in lane 1 of Fig. 3 , anti-PPAR-γ antibody detected a band (designated as band P; arrowhead) larger than that for the PPAR-γ1 protein, which was the expected molecular size ( 52 kDa) (23) (designated PPAR-γ1; arrow) when nuclear extracts of VSMCs cultured in regular media (with 10% fetal bovine serum) were used. Although the amounts of the lower band (PPAR-γ1) and the upper band (P) were almost equal when VSMCs were cultured in regular media (Fig. 3, lane 1) , the amounts of the upper band (P) dramatically decreased ( 40% of the lower band in lane 2, and 30% of the lower band in lane 3) when VSMCs were treated with MAP kinase kinase inhibitor PD98059 (Fig. 3, lane 2) or cultured in serum-free media (with 0% fetal bovine serum) (Fig. 3, lane 3) . Anti-PPAR-γ 2 antibody recognizing only the PPAR-γ 2 protein could not detect both of these bands (Fig. 3, lane 4) , indicating that the larger band (P) did not represent the PPAR-γ 2 protein. These data strongly suggest that the larger band (P) represents phosphorylated PPAR-γ1 at the basal state by the MAP kinase pathway, which may be activated by growth factors involved in the serum. Taken together, these data suggest that inhibition of the MAP kinase pathway augmented the suppression of PPAR-γ-mediated AT1R gene transcription, most likely by activation of PPAR-γ through inhibition of its phosphorylation.
Effect of CBP Overexpression on AT1R Gene Transcription Suppression
Since CBP is known to interact with PPAR-γ and modulate its function (14), we next examined the effect of CBP overexpression on PPAR-γ-mediated AT1R gene transcription suppression. As shown in Fig. 4 , PGJ2-mediated suppression of the transcription of 1969/ 104-luc (line 2) was partially, but significantly, abrogated by CBP overexpression in proportion to the transfected amounts (lines 3 and 4). Since the suppression of PPAR-γ-mediated AT1R gene transcription was mediated through the 58/ 34 GC-box related element (12), we next studied the effect of CBP overexpression on the 58/ 1-luc transcription suppression. Although CBP overexpression showed little effect on the basal transcription level of 58/ 1-luc (Fig. 5, lines 1 and 4) , transcription suppression of 58/ 1-luc either by PGJ2 (Fig. 5 , lines 2 and 5) or by troglitazone (Fig. 5, lines 3 and 6 ) was significantly abrogated by CBP overexpression. We next transfected mutated 58/ 1-luc whose GC-box related sequence within the 58/ 34 region was disrupted (12) . The transcription activity of mutated 58/ 1-luc was not affected by both PPAR-γ ligands (Fig. 5, lines 7-9 ) as previously observed (12) , further confirming that the 58/ 34 GC-box related element was responsible for the PPAR-γ-mediated suppression of AT1R gene transcription. Interestingly, CBP overexpression did not affect the mutated 58/ 1-luc activity either in the absence (Fig. 5, line 10 ) or presence (Fig. 5, lines 11 and 12 ) of PPAR-γ ligands, suggesting that the 58/ 34 GC-box related element was also necessary for the CBP effect. An increase of CBP protein by CBP overexpression was confirmed by Western immunoblot analyses using anti-CBP antibody (data not shown). These data suggest that the abrogation of PPAR-γ-mediated AT1R gene transcription suppression by CBP may be mediated through the 58/ 34 GC-box related element, most likely by activation of the remaining Sp1.
Discussion
In VSMCs, the MAP kinase pathway plays major roles in AII-induced c-fos induction, cell migration, and DNA synthesis (15) . In addition to AII signaling, the MAP kinase pathway is also involved in insulin (25) , platelet derived growth factor (PDGF) (26) , and tumor necrosis factor (TNF)-α (27) signaling in VSMCs, leading to the progression of atherosclerosis. The PPAR-γ ligand troglitazone has recently been reported to inhibit AII-induced DNA synthesis and migration of VSMCs through the inhibition of MAP kinase translocation and activation (28, 29) . In the present study, we observed that inhibition of the MAP kinase pathway, but not inhibition of the p38 kinase pathway, augmented the suppression of PPAR-γ-mediated AT1R gene transcription. Phosphorylation of PPAR-γ by the MAP kinase pathway is known to inhibit PPAR-γ activity (13) . Therefore, it is reasonable to assume that the observed augmentation of PPAR-γ-mediated AT1R gene transcription suppression by inhibition of the MAP kinase pathway may have been due to the activation of PPAR-γ by the inhibition of its phosphorylation. Since many growth factors, including AII (15), insulin (25) , PDGF (26) , and TNF-α (27) , are known to activate the MAP kinase pathway in VSMCs, PPAR-γ may be prone to be phosphorylated by the MAP kinase pathway under regular culture conditions (10% fetal bovine serum) (12) and in vivo. Half amounts of PPAR-γ1 in 3T3-L1 cells are reported to be phosphorylated by MAP kinase pathway in the basal state (13) , which is consistent with our observation in VSMCs. It is therefore speculated that vascular PPAR-γ function may be attenuated by MAP kinase pathway-mediated phosphorylation in patients with atherosclerosis, hypertension, obesity, and hyperinsulinemia whose growth factors described above may be elevated. PPAR-γ phosphorylation by the MAP kinase pathway may thus attenuate PPAR-γ-mediated AT1R gene transcription suppression through the inhibition of PPAR-γ activity, leading to atherogenesis. This is a novel mechanism of MAP kinase pathway on the expression regulation of AT1R.
Co-activator CBP/p300 is known to interact with PPAR-γ through its LXXLL motif, and modulate PPAR-γ function (14) . In addition to interacting with transcription factors, CBP/p300 also induces transcription activation through its intrinsic histone acetyltransferase (HAT) activity (30) . Recently, HAT activity of CBP has been reported to be enhanced in atherosclerotic lesions in VSMCs (16) . Interestingly, the HAT activity is activated by MAP kinase-induced CBP phosphorylation (31) . Moreover, CBP/p300 is well known to activate the transcription of nuclear factor-κB, which may lead to atherogenesis (32) . Therefore, activation of CBP in VSMCs may be more atherogenic rather than antiatherogenic. In the present study, we observed that CBP overexpression could abrogate PPAR-γ-mediated AT1R gene transcription suppression through the 58/ 34 GCbox related element. We previously reported that Sp1 could bind to and activate the 58/ 34 GC-box related element (12) . Since CBP/p300 is reported to interact with Sp1 (33, 34) and enhance its DNA binding (33) , it is reasonable to assume that CBP may abrogate PPAR-γ-mediated AT1R gene transcription suppression through the enhancement of the Sp1 activity remained on the 58/ 34 GC-box related element. The MAP kinase pathway and CBP may thus antagonize against PPAR-γ in AT1R gene transcription, probably leading to the progression of atherosclerosis. 
